Malabsorption News

The phrase “gluten-free” has become ubiquitous in American diet culture, and is a fixture in grocery store aisles, cookbooks and restaurant menus. Regardless of whether consumers truly understand the objectives of this diet or the specific population it is designed to serve, “gluten-free” seems to have become a catch-all synonym for “healthy.” Gluten-free weight loss diets are widely promoted and adopted, and diets eliminating wheat have been suggested as a means of reversing medical conditions from high blood sugar to minor rashes.

Relative proportions of celiac disease and non-celiac gluten sensitivity among individuals who avoid dietary gluten vary significantly across the U.S. and the world, according to new research.

Patients with celiac disease who were seropositive despite adhering to a gluten-free diet experienced significant improvement in symptoms when taking latiglutenase with meals, according to a post hoc analysis of the CeliAction study.

Ritter Pharmaceuticals announced plans for phase 3 development of its novel prebiotic for the treatment of lactose intolerance after meeting with the FDA.

RP-G28, a novel non-digestible oligosaccharide designed to stimulate the gut microbiota to metabolize lactose, significantly reduced symptoms in patients with lactose intolerance, according to a press release.

Patients diagnosed with nonceliac wheat sensitivity continued to experience symptoms when exposed to wheat over a median study period of more than 8 years, leading researchers to conclude that the condition is persistent.

Alcresta Therapeutics, Inc. has received 510(k) clearance from the FDA for the use of its digestive enzyme cartridge Relizorb in pediatric patients as young as 5 years old with fat malabsorption, according to a press release.

Infants with genetic risk factors for celiac disease who avoided cow’s milk-based formula were just as likely to develop the disease later in life as those who did not, according to the results of a Finnish randomized controlled trial.

Based on findings of an international registry study, researchers recommend screening children and adolescents with type 1 diabetes for coexisting celiac disease and monitoring the height of those with coexisting diseases.

The risk for developing celiac disease was increased in children who had a gastrointestinal or respiratory infection during their first year of life, especially among those with multiple GI infections, according to the results of a German study.